Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-CD19CD20-ALLO1 in Severe, Treatment-refractory Systemic Lupus Erythematosus
NCT06984341Phase 1Withdrawn
- Sponsor
- Genentech
- Start
- Jun 2026
- Primary completion
- Nov 2033
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of P-CD19CD20-ALLO1 in systemic lupus erythematosus (SLE) (3 arms), sponsored by Genentech. Primary endpoints: Dose-limiting Toxicities at 29 days and Adverse Events at 5 years. Planned start Jun 2026; status: withdrawn.
02
Drugs
P-CD19CD20-ALLO1
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06984341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984341.